📊 ZNTL Key Takeaways
Is Zentalis Pharmaceuticals, Inc. (ZNTL) a Good Investment?
Zentalis is a pre-revenue clinical-stage pharmaceutical company burning $125.2M annually with only $36M in cash, providing approximately 3.5 months of operational runway. The zero revenue, unsustainable cash burn relative to available liquidity, and dependence on successful clinical outcomes create an existential financial risk with high probability of near-term capital needs or insolvency.
Why Buy Zentalis Pharmaceuticals, Inc. Stock? ZNTL Key Strengths
- Strong equity position of $216.2M provides financial cushion and absorbs operational losses
- Zero debt eliminates debt servicing pressure and interest obligations
- Excellent current ratio of 6.93x indicates strong short-term asset liquidity position
ZNTL Stock Risks: Zentalis Pharmaceuticals, Inc. Investment Risks
- Zero revenue with no approved commercial products; purely pre-revenue development stage
- Critical cash runway of 3.5 months at current $125.2M annual burn rate against $36M available cash
- Imminent capital requirements through equity raise (significant dilution) or debt financing
- Complete dependence on clinical trial success and FDA regulatory approval for any revenue realization
- Negative operating cash flow of $125.2M with no visible profitability pathway
Key Metrics to Watch
- Quarterly cash position and monthly burn rate trends for runway sustainability
- Clinical trial advancement milestones and regulatory approval timelines for pipeline candidates
- Capital raise announcements including dilution impact and funding adequacy
Zentalis Pharmaceuticals, Inc. (ZNTL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.93x current ratio provides a solid financial cushion.
ZNTL Profit Margin, ROE & Profitability Analysis
ZNTL vs Healthcare Sector: How Zentalis Pharmaceuticals, Inc. Compares
How Zentalis Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zentalis Pharmaceuticals, Inc. Stock Overvalued? ZNTL Valuation Analysis 2026
Based on fundamental analysis, Zentalis Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zentalis Pharmaceuticals, Inc. Balance Sheet: ZNTL Debt, Cash & Liquidity
ZNTL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zentalis Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.47 indicates the company is currently unprofitable.
ZNTL Revenue Growth, EPS Growth & YoY Performance
ZNTL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$26.7M | $-0.37 |
| Q2 2025 | N/A | -$26.9M | $-0.37 |
| Q1 2025 | N/A | $10.1M | $0.14 |
| Q3 2024 | N/A | -$40.2M | $-0.56 |
| Q2 2024 | N/A | -$78.2M | $-1.10 |
| Q1 2024 | N/A | $10.1M | $0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zentalis Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ZNTL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zentalis Pharmaceuticals, Inc. (CIK: 0001725160)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZNTL
What is the AI rating for ZNTL?
Zentalis Pharmaceuticals, Inc. (ZNTL) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZNTL's key strengths?
Claude: Strong equity position of $216.2M provides financial cushion and absorbs operational losses. Zero debt eliminates debt servicing pressure and interest obligations.
What are the risks of investing in ZNTL?
Claude: Zero revenue with no approved commercial products; purely pre-revenue development stage. Critical cash runway of 3.5 months at current $125.2M annual burn rate against $36M available cash.
What is ZNTL's revenue and growth?
Zentalis Pharmaceuticals, Inc. reported revenue of $0.0.
Does ZNTL pay dividends?
Zentalis Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ZNTL SEC filings?
Official SEC filings for Zentalis Pharmaceuticals, Inc. (CIK: 0001725160) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZNTL's EPS?
Zentalis Pharmaceuticals, Inc. has a diluted EPS of $-1.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ZNTL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Zentalis Pharmaceuticals, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ZNTL stock overvalued or undervalued?
Valuation metrics for ZNTL: ROE of -63.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ZNTL stock in 2026?
Our dual AI analysis gives Zentalis Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZNTL's free cash flow?
Zentalis Pharmaceuticals, Inc.'s operating cash flow is $-125.2M, with capital expenditures of $0.0.
How does ZNTL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -63.4% (avg: 15%), current ratio 6.93 (avg: 2).